Completed PHASE1 INTERVENTIONAL 2-arm NCT00652795

Bioequivalence Study Doxycycline Tablets and Monodox Capsules Under Fasting Conditions

Randomized, 2-Way Crossover, Bioequivalence Study of Doxycycline 150 mg Tablet and Monodox 50 mg Capsule Administered as 1 x 150 mg Tablet or 3 x 50 mg Capsules in Healthy Subjects Under Fasting Conditions

Sponsor: Anapharm

Conditions To Determine Bioequivalence Under Fasting Conditions

Interventions Doxycycline Monohydrate Monodox

Updated 5 times since 2017 Last updated: Apr 1, 2008 Started: Jul 31, 2004 Primary completion: Sep 30, 2004 Completion: Sep 30, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on To Determine Bioequivalence Under Fasting Conditions, this trial is completed. The trial is conducted by Anapharm and has accumulated 5 data snapshots since 2004. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Feb 2017 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Jul 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Anapharm
Par Pharmaceutical, Inc.

Data source: Par Pharmaceutical, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Sainte-Foy, Canada